Uncertainty over Perrigo takeover rumors

16 June 2016
mergers-acquisitions-big

It has been a turbulent few days for shares in Ireland-headquartered Perrigo (NYSE: PRGO) as word that it might be taken over by a UK-based company prompted rumors and counter-rumors.

A source from finance website StreetInsider claimed on Tuesday that the consumer and generic drug firm was close to being bought for $20 million.

This prompted Perrigo’s share price to rocket that day by 9% as investors jumped on the speculation, about which the company declined to comment. On Wednesday the share price promptly dropped by 9% as analysts considered the likelihood of the takeover going ahead.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical